Skip to main content

Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran

High Blood Pressure & Cardiovascular Prevention volume 23, pages 115–122 (2016)Cite this article

Abstract

Vitamin K-dependent antagonists (VKAs) are the most commonly used oral anticoagulants. Non-VKA oral anticoagulants (NOACs), directly target factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, and edoxaban) have predictable pharmacological effects and relatively few drug and food interactions compared with VKA. Among NOACs, dabigatran has been extensively tested for stroke prevention in patients with non-valvular atrial fibrillation eligible for oral anticoagulation with VKA. Dabigatran is at least as effective as warfarin at preventing stroke with advantages of less serious bleeding except for gastrointestinal bleeding, which occurs more often than with warfarin. The findings of dabigatran use in randomized trials, post market registries and specific clinical settings are discussed in this article.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386:281–91.

    CAS  Article  PubMed  Google Scholar 

  2. Verheugt FWA, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015;386:303–10.

    CAS  Article  PubMed  Google Scholar 

  3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD. Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    CAS  Article  PubMed  Google Scholar 

  4. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–6.

    CAS  Article  PubMed  Google Scholar 

  5. Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788–90.

    CAS  Article  PubMed  Google Scholar 

  6. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study. Circulation. 2013;128:237–43.

    CAS  Article  PubMed  Google Scholar 

  7. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272–4.

    CAS  Article  PubMed  Google Scholar 

  8. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.

    CAS  Article  PubMed  Google Scholar 

  9. Sørensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbøl EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Weeke P, Lip GYH, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open; 2013:3(5).

  10. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GYH. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation. J Am Coll Cardiol. 2013;61:2264–73.

    CAS  Article  PubMed  Google Scholar 

  11. Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial firbrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.

    CAS  Article  PubMed  Google Scholar 

  12. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–39.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. Reilly PA, Lehr T, Haertter S, The RE-LY Investigators, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8.

    CAS  Article  PubMed  Google Scholar 

  14. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    CAS  Article  PubMed  Google Scholar 

  15. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–20.

    CAS  Article  PubMed  Google Scholar 

  16. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127:634–40.

    CAS  Article  PubMed  Google Scholar 

  17. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.

    CAS  Article  PubMed  Google Scholar 

  18. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–44.

    Article  PubMed  Google Scholar 

  19. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10:483–9.

    Article  PubMed  Google Scholar 

  20. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168–74.

    CAS  Article  PubMed  Google Scholar 

  21. Camm AJ, Lip GYH, De Caterina R, And the ESC Committee for Practice Guidelines (CPG), et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.

    Article  PubMed  Google Scholar 

  22. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

    CAS  Article  PubMed  Google Scholar 

  23. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    CAS  Article  PubMed  Google Scholar 

  24. Losi MA, Izzo R, De Marco M, Canciello G, Rapacciuolo A, Trimarco V, Stabile E, Rozza F, Esposito G, De Luca N, de Simone G, Trimarco B. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. Int J Cardiol. 2015;15(199):290–5.

    Article  Google Scholar 

  25. Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, Connolly SJ, Yusuf S, Ezekowitz MD. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116(8):1204–9.

    CAS  Article  PubMed  Google Scholar 

  26. Eikelboom JW, Connolly SJ, Brueckmann M, The RE-ALIGN Investigators, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.

    CAS  Article  PubMed  Google Scholar 

  27. Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101 801 patients. Mayo Clin Proc. 2014;89:896–907.

    Article  PubMed  Google Scholar 

  28. Kate M, Gioia L, Buck B, Sivakumar L, Jeerakathil T, Shuaib A, Butcher K. Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation. Stroke. 2015;46(9):2685–7.

    CAS  Article  PubMed  Google Scholar 

  29. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S–16S.

    CAS  Article  PubMed  Google Scholar 

  30. Fusaro M, Dalle Carbonare L, Dusso A, Arcidiacono MV, Valenti MT, Aghi A, Pasho S, Gallieni M. Differential effects of dabigatran and warfarin on bone volume and structure in rats with normal renal function. PLoS One. 2015;10(8):e0133847.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–96.

    CAS  Article  PubMed  Google Scholar 

  32. Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison of the Short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists a french nationwide propensity-matched cohort study. Circulation. 2015;132:1252–60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Cardiology, Department of Advanced Biomedical Sciences, Hypertension Research Centre, University of Napoli “Federico II”, Naples, Italy

    Eugenio Stabile, Raffaele Izzo, Francesco Rozza, Maria Angela Losi & Bruno Trimarco

  2. Department of Cardiac Surgery, Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi D’aragona, Salerno, Italy

    Enrico Coscioni

Authors
  1. Eugenio Stabile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raffaele Izzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Rozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Angela Losi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Enrico Coscioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruno Trimarco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugenio Stabile.

Ethics declarations

Conflict of interest

Enrico Coscioni: No conflicts to disclose. Eugenio Stabile: No Conflicts of interests to disclose. Raffaele Izzo: No Conflicts of interests to disclose. Francesco Rozza: No Conflicts of interests to disclose. Maria Angela Losi: No Conflicts of interests to disclose. Bruno Trimarco: No Conflicts of interests to disclose

Research involving human participants and/or animals

This article does not contain any study with humans or animals performed by any of the authors.

Informed consent

For this type of study a formal consent is not required.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stabile, E., Izzo, R., Rozza, F. et al. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. High Blood Press Cardiovasc Prev 23, 115–122 (2016). https://doi.org/10.1007/s40292-016-0150-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-016-0150-7

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Bleeding
  • Stroke